Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

128 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease.
Jones WS, Baumgartner I, Hiatt WR, Heizer G, Conte MS, White CJ, Berger JS, Held P, Katona BG, Mahaffey KW, Norgren L, Blomster J, Millegård M, Reist C, Patel MR, Fowkes FG; International Steering Committee and Investigators of the EUCLID Trial. Jones WS, et al. Among authors: reist c. Circulation. 2017 Jan 17;135(3):241-250. doi: 10.1161/CIRCULATIONAHA.116.025880. Epub 2016 Nov 13. Circulation. 2017. PMID: 27840336 Clinical Trial.
Design and rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) trial.
Berger JS, Katona BG, Jones WS, Patel MR, Norgren L, Baumgartner I, Blomster J, Mahaffey KW, Held P, Millegård M, Heizer G, Reist C, Fowkes FG, Hiatt WR. Berger JS, et al. Among authors: reist c. Am Heart J. 2016 May;175:86-93. doi: 10.1016/j.ahj.2016.01.018. Epub 2016 Jan 28. Am Heart J. 2016. PMID: 27179727 Free article. Clinical Trial.
Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease.
Hiatt WR, Fowkes FG, Heizer G, Berger JS, Baumgartner I, Held P, Katona BG, Mahaffey KW, Norgren L, Jones WS, Blomster J, Millegård M, Reist C, Patel MR; EUCLID Trial Steering Committee and Investigators. Hiatt WR, et al. Among authors: reist c. N Engl J Med. 2017 Jan 5;376(1):32-40. doi: 10.1056/NEJMoa1611688. Epub 2016 Nov 13. N Engl J Med. 2017. PMID: 27959717 Free article. Clinical Trial.
Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial.
Berger JS, Abramson BL, Lopes RD, Heizer G, Rockhold FW, Baumgartner I, Fowkes FGR, Held P, Katona BG, Norgren L, Jones WS, Millegård M, Blomster J, Reist C, Hiatt WR, Patel MR, Mahaffey KW. Berger JS, et al. Among authors: reist c. Vasc Med. 2018 Dec;23(6):523-530. doi: 10.1177/1358863X18775594. Epub 2018 Jul 11. Vasc Med. 2018. PMID: 29992857 Clinical Trial.
Assessment of North American Clinical Research Site Performance During the Start-up of Large Cardiovascular Clinical Trials.
Goyal A, Schibler T, Alhanti B, Hannan KL, Granger CB, Blazing MA, Lopes RD, Alexander JH, Peterson ED, Rao SV, Green JB, Roe MT, Rorick T, Berdan LG, Reist C, Mahaffey KW, Harrington RA, Califf RM, Patel MR, Hernandez AF, Jones WS. Goyal A, et al. Among authors: reist c. JAMA Netw Open. 2021 Jul 1;4(7):e2117963. doi: 10.1001/jamanetworkopen.2021.17963. JAMA Netw Open. 2021. PMID: 34297072 Free PMC article.
High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial.
Mahaffey KW, Cohen M, Garg J, Antman E, Kleiman NS, Goodman SG, Berdan LG, Reist CJ, Langer A, White HD, Aylward PE, Col JJ, Ferguson JJ 3rd, Califf RM; SYNERGY Trial Investigators. Mahaffey KW, et al. JAMA. 2005 Nov 23;294(20):2594-600. doi: 10.1001/jama.294.20.2594. JAMA. 2005. PMID: 16304073 Clinical Trial.
Prediction of one-year survival in high-risk patients with acute coronary syndromes: results from the SYNERGY trial.
Mahaffey KW, Yang Q, Pieper KS, Antman EM, White HD, Goodman SG, Cohen M, Kleiman NS, Langer A, Aylward PE, Col JJ, Reist C, Ferguson JJ, Califf RM; SYNERGY Trial Investigators. Mahaffey KW, et al. Among authors: reist c. J Gen Intern Med. 2008 Mar;23(3):310-6. doi: 10.1007/s11606-007-0498-4. Epub 2008 Jan 15. J Gen Intern Med. 2008. PMID: 18196350 Free PMC article. Clinical Trial.
Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome.
Becker RC, Mahaffey KW, Yang H, Marian AJ, Furman MI, Michael Lincoff A, Hazen SL, Petersen JL, Reist CJ, Kleiman NS; SYNERGY Investigators. Becker RC, et al. Among authors: reist cj. J Thromb Thrombolysis. 2011 Feb;31(2):146-53. doi: 10.1007/s11239-010-0532-y. J Thromb Thrombolysis. 2011. PMID: 21086021 Clinical Trial.
Comparison of site-reported and core laboratory-reported creatine kinase-MB values in non-ST-segment elevation acute coronary syndrome (from the international trial SYNERGY).
Linefsky JP, Lin M, Pieper KS, Reist CJ, Berdan LG, Antman EM, Goodman SG, French JK, Guneri S, Roe MT, Newby LK, Harrington RA, Ferguson JJ, Califf RM, Mahaffey KW. Linefsky JP, et al. Am J Cardiol. 2009 Nov 15;104(10):1330-5. doi: 10.1016/j.amjcard.2009.06.056. Epub 2009 Sep 25. Am J Cardiol. 2009. PMID: 19892046 Clinical Trial.
128 results